<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781998</url>
  </required_header>
  <id_info>
    <org_study_id>SaxPsychiatry</org_study_id>
    <nct_id>NCT04781998</nct_id>
  </id_info>
  <brief_title>Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?</brief_title>
  <official_title>Is Pharmacological Treatment With the Glucagon-like Peptide-1 Receptor Agonist Liraglutide 3mg (Saxenda®) Once-daily a Viable Treatment for Weight Management in Forensic Psychiatry Patients? A Feasibility Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anders Fink-Jensen, MD, DMSci</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Psychiatric Centre Rigshospitalet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, multi-centre, 26-weeks clinical feasibility study. The objective is to explore&#xD;
      whether Saxenda could be a feasible choice in the treatment of overweight, obesity and&#xD;
      weight-related medical problems, in patients diagnosed with a severe mental illness and&#xD;
      hospitalized at a forensic department in Denmark. We wish to determine the viability of the&#xD;
      daily Saxenda®-injection treatment in this specific patient group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>An open-label, multi-centre, 26-weeks clinical feasibility study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the number of &quot;completers&quot;</measure>
    <time_frame>26 weeks</time_frame>
    <description>Feasibility in this study is defined as a minimum of 75% completers with a confidence interval of ±10%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reason(s) for drop-out</measure>
    <time_frame>26 weeks</time_frame>
    <description>The reason for withdrawal may be the withdrawal of consent, any use of coercive measures, failure to maintain a present level of compliance with the clinical trial medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>26 weeks</time_frame>
    <description>Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>26 weeks</time_frame>
    <description>mmol/mol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>26 weeks</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>26 weeks</time_frame>
    <description>Beats/minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FIB-4 score</measure>
    <time_frame>26 weeks</time_frame>
    <description>index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>26 weeks</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mental Disorder</condition>
  <condition>Metabolic Disturbance</condition>
  <condition>Feasibility</condition>
  <condition>Overweight and Obesity</condition>
  <condition>Liraglutide</condition>
  <arm_group>
    <arm_group_label>liraglutide 3 mg (Saxenda®) once-daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide 3 mg (Saxenda®) once-daily</intervention_name>
    <description>Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.</description>
    <arm_group_label>liraglutide 3 mg (Saxenda®) once-daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed oral and written consent&#xD;
&#xD;
          2. Diagnosed with a mental illness according to the criteria of ICD10&#xD;
&#xD;
          3. Hospitalised at a forensic psychiatric department during the full inclusion period&#xD;
&#xD;
          4. Age 18 years to 65 years (both included)&#xD;
&#xD;
          5. BMI ≥27 kg/m2 with one or more weight-related comorbidities (sleep apnea, hypertension&#xD;
             (BT ≥ 140/90 mmHg with no antihypertensive treatment. BT ≥ 130/80 mmHg with&#xD;
             antihypertensive treatment), dyslipidaemia (LDL cholesterol ≥ 3 mmol/L), pre-diabetes&#xD;
             (HbA1c 39-47 mmol/mol) or type 2 diabetes (HbA1c ≥ 48 mmol/mol)) or BMI ≥30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any use of coercive measures according to the Danish law for Mental&#xD;
             Health/Psykiatriloven (as defined in &quot;Informationsbekendtgørelsen § 10&quot;).&#xD;
&#xD;
          2. Fertile females of child-bearing potential who are pregnant, breast-feeding or have&#xD;
             the intention of becoming pregnant&#xD;
&#xD;
          3. Women who are not willing to use an adequate contraceptive considered as highly&#xD;
             effective (IUD or hormonal contraception during the full length of the study&#xD;
&#xD;
          4. Impaired hepatic function (plasma liver transaminases &gt;2 times the upper normal limit)&#xD;
&#xD;
          5. Impaired renal function (serum creatinine &gt;150 μmol/l and/or macroalbuminuria)&#xD;
&#xD;
          6. Impaired pancreatic function (acute or chronic pancreatitis and/or plasma amylase &gt;2&#xD;
             times the upper normal limit)&#xD;
&#xD;
          7. Cardiac problems defined as decompensated heart failure (NYHA class III/IV), unstable&#xD;
             angina pectoris and/or myocardial infarction within the last 12 months&#xD;
&#xD;
          8. Hypertension with systolic blood pressure &gt;180 mmHg or diastolic blood pressure &gt;100&#xD;
             mmHg&#xD;
&#xD;
          9. Any condition that the investigator feels would interfere with trial participation&#xD;
&#xD;
         10. Use of weight-lowering pharmacotherapy within the preceding 3 months&#xD;
&#xD;
         11. Type 1 diabetes&#xD;
&#xD;
         12. Patients treated with insulin&#xD;
&#xD;
         13. Patients treated with other GLP-1 receptor agonist medicines&#xD;
&#xD;
         14. Known allergy to liraglutide or any of the ingredients in Saxenda®&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie R Sass, MD</last_name>
    <phone>+4538647072</phone>
    <email>marie.reeberg.sass@regionh.dk</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Psychiatric Centre Rigshospitalet</investigator_affiliation>
    <investigator_full_name>Anders Fink-Jensen, MD, DMSci</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

